These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 18480090)

  • 21. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies.
    He Y; Lu H; Siddiqui P; Zhou Y; Jiang S
    J Immunol; 2005 Apr; 174(8):4908-15. PubMed ID: 15814718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased antibody affinity confers broad in vitro protection against escape mutants of severe acute respiratory syndrome coronavirus.
    Rani M; Bolles M; Donaldson EF; Van Blarcom T; Baric R; Iverson B; Georgiou G
    J Virol; 2012 Sep; 86(17):9113-21. PubMed ID: 22696652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
    See RH; Zakhartchouk AN; Petric M; Lawrence DJ; Mok CPY; Hogan RJ; Rowe T; Zitzow LA; Karunakaran KP; Hitt MM; Graham FL; Prevec L; Mahony JB; Sharon C; Auperin TC; Rini JM; Tingle AJ; Scheifele DW; Skowronski DM; Patrick DM; Voss TG; Babiuk LA; Gauldie J; Roper RL; Brunham RC; Finlay BB
    J Gen Virol; 2006 Mar; 87(Pt 3):641-650. PubMed ID: 16476986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins.
    Wang SF; Tseng SP; Yen CH; Yang JY; Tsao CH; Shen CW; Chen KH; Liu FT; Liu WT; Chen YM; Huang JC
    Biochem Biophys Res Commun; 2014 Aug; 451(2):208-14. PubMed ID: 25073113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV.
    Yasui F; Kai C; Kitabatake M; Inoue S; Yoneda M; Yokochi S; Kase R; Sekiguchi S; Morita K; Hishima T; Suzuki H; Karamatsu K; Yasutomi Y; Shida H; Kidokoro M; Mizuno K; Matsushima K; Kohara M
    J Immunol; 2008 Nov; 181(9):6337-48. PubMed ID: 18941225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS.
    Yip MS; Leung HL; Li PH; Cheung CY; Dutry I; Li D; Daëron M; Bruzzone R; Peiris JS; Jaume M
    Hong Kong Med J; 2016 Jun; 22(3 Suppl 4):25-31. PubMed ID: 27390007
    [No Abstract]   [Full Text] [Related]  

  • 27. SARS-like WIV1-CoV poised for human emergence.
    Menachery VD; Yount BL; Sims AC; Debbink K; Agnihothram SS; Gralinski LE; Graham RL; Scobey T; Plante JA; Royal SR; Swanstrom J; Sheahan TP; Pickles RJ; Corti D; Randell SH; Lanzavecchia A; Marasco WA; Baric RS
    Proc Natl Acad Sci U S A; 2016 Mar; 113(11):3048-53. PubMed ID: 26976607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease.
    Netland J; DeDiego ML; Zhao J; Fett C; Álvarez E; Nieto-Torres JL; Enjuanes L; Perlman S
    Virology; 2010 Mar; 399(1):120-128. PubMed ID: 20110095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge.
    Rockx B; Corti D; Donaldson E; Sheahan T; Stadler K; Lanzavecchia A; Baric R
    J Virol; 2008 Apr; 82(7):3220-35. PubMed ID: 18199635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunological detection of severe acute respiratory syndrome coronavirus by monoclonal antibodies.
    Ohnishi K; Sakaguchi M; Kaji T; Akagawa K; Taniyama T; Kasai M; Tsunetsugu-Yokota Y; Oshima M; Yamamoto K; Takasuka N; Hashimoto S; Ato M; Fujii H; Takahashi Y; Morikawa S; Ishii K; Sata T; Takagi H; Itamura S; Odagiri T; Miyamura T; Kurane I; Tashiro M; Kurata T; Yoshikura H; Takemori T
    Jpn J Infect Dis; 2005 Apr; 58(2):88-94. PubMed ID: 15858286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chicken single-chain variable fragments against the SARS-CoV spike protein.
    Lee YC; Leu SJ; Hu CJ; Shih NY; Huang IJ; Wu HH; Hsieh WS; Chiang BL; Chiu WT; Yang YY
    J Virol Methods; 2007 Dec; 146(1-2):104-11. PubMed ID: 17643500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses.
    Zeng LP; Ge XY; Peng C; Tai W; Jiang S; Du L; Shi ZL
    Sci China Life Sci; 2017 Dec; 60(12):1399-1402. PubMed ID: 29134417
    [No Abstract]   [Full Text] [Related]  

  • 33. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity.
    Du L; Zhao G; Chan CC; Sun S; Chen M; Liu Z; Guo H; He Y; Zhou Y; Zheng BJ; Jiang S
    Virology; 2009 Oct; 393(1):144-50. PubMed ID: 19683779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.
    Bolles M; Deming D; Long K; Agnihothram S; Whitmore A; Ferris M; Funkhouser W; Gralinski L; Totura A; Heise M; Baric RS
    J Virol; 2011 Dec; 85(23):12201-15. PubMed ID: 21937658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters.
    Roberts A; Thomas WD; Guarner J; Lamirande EW; Babcock GJ; Greenough TC; Vogel L; Hayes N; Sullivan JL; Zaki S; Subbarao K; Ambrosino DM
    J Infect Dis; 2006 Mar; 193(5):685-92. PubMed ID: 16453264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies.
    Zhang H; Wang G; Li J; Nie Y; Shi X; Lian G; Wang W; Yin X; Zhao Y; Qu X; Ding M; Deng H
    J Virol; 2004 Jul; 78(13):6938-45. PubMed ID: 15194770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of SARS inactivated vaccine in BALB/c mice.
    Xiong S; Wang YF; Zhang MY; Liu XJ; Zhang CH; Liu SS; Qian CW; Li JX; Lu JH; Wan ZY; Zheng HY; Yan XG; Meng MJ; Fan JL
    Immunol Lett; 2004 Sep; 95(2):139-43. PubMed ID: 15388253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model.
    Ishii K; Hasegawa H; Nagata N; Ami Y; Fukushi S; Taguchi F; Tsunetsugu-Yokota Y
    Microbiol Immunol; 2009 Feb; 53(2):75-82. PubMed ID: 19291090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fully human monoclonal antibody directed to proteolytic cleavage site in severe acute respiratory syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model.
    Miyoshi-Akiyama T; Ishida I; Fukushi M; Yamaguchi K; Matsuoka Y; Ishihara T; Tsukahara M; Hatakeyama S; Itoh N; Morisawa A; Yoshinaka Y; Yamamoto N; Lianfeng Z; Chuan Q; Kirikae T; Sasazuki T
    J Infect Dis; 2011 Jun; 203(11):1574-81. PubMed ID: 21592986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system.
    Wang S; Chou TH; Sakhatskyy PV; Huang S; Lawrence JM; Cao H; Huang X; Lu S
    J Virol; 2005 Feb; 79(3):1906-10. PubMed ID: 15650214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.